Intellia Therapeutics, Inc. (NTLA)
12.76
+0.08
(+0.59%)
USD |
NASDAQ |
Sep 02, 16:00
12.92
+0.16
(+1.25%)
After-Hours: 06:51
Intellia Therapeutics Research and Development Expense (TTM) : 337.63M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 337.63M |
| March 31, 2026 | 351.67M |
| December 31, 2025 | 379.07M |
| September 30, 2025 | 407.11M |
| June 30, 2025 | 435.55M |
| March 31, 2025 | 452.62M |
| December 31, 2024 | 456.03M |
| September 30, 2024 | 448.23M |
| June 30, 2024 | 438.86M |
| March 31, 2024 | 440.36M |
| December 31, 2023 | 426.09M |
| September 30, 2023 | 417.58M |
| June 30, 2023 | 400.88M |
| March 31, 2023 | 376.13M |
| December 31, 2022 | 412.41M |
| September 30, 2022 | 383.68M |
| June 30, 2022 | 347.68M |
| March 31, 2022 | 316.57M |
| December 31, 2021 | 222.92M |
| September 30, 2021 | 190.26M |
| Date | Value |
|---|---|
| June 30, 2021 | 169.72M |
| March 31, 2021 | 148.67M |
| December 31, 2020 | 144.10M |
| September 30, 2020 | 139.20M |
| June 30, 2020 | 128.56M |
| March 31, 2020 | 117.81M |
| December 31, 2019 | 108.41M |
| September 30, 2019 | 96.60M |
| June 30, 2019 | 92.32M |
| March 31, 2019 | 90.33M |
| December 31, 2018 | 89.12M |
| September 30, 2018 | 90.37M |
| June 30, 2018 | 84.61M |
| March 31, 2018 | 76.71M |
| December 31, 2017 | 67.65M |
| September 30, 2017 | 57.81M |
| June 30, 2017 | 48.19M |
| March 31, 2017 | 40.05M |
| December 31, 2016 | 31.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Beam Therapeutics, Inc. | 408.66M |
| Twist Bioscience Corp. | 71.86M |
| Tenaya Therapeutics, Inc. | 61.61M |
| Moderna, Inc. | 2.635B |
| Revolution Medicines, Inc. | 1.287B |